Lunit (KRX:328130), a provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, announced on Wednesday that it has formed a strategic partnership with CellCarta, a provider of CRO laboratory services for pharmaceutical research and development.

Under the collaboration, Lunit's AI pathology solutions will be offered as part of CellCarta's services for global clinical trials, making it easier for pharma sponsors to adopt AI-powered analysis within existing trial workflows.

This global alliance aims to broaden access to the Lunit SCOPE suite, Lunit's digital pathology AI solution, and deliver faster, more scalable insights into tumour biology through the analysis of H&E and IHC whole slide images. These insights help identify patients likely to benefit from specific therapies, support biomarker development, and ultimately advance precision oncology and drug development.